Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Envveno Medical Corp (NVNO)

Envveno Medical Corp (NVNO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 49,451
  • Shares Outstanding, K 17,536
  • Annual Sales, $ 0 K
  • Annual Income, $ -23,520 K
  • EBIT $ -23 M
  • EBITDA $ -23 M
  • 60-Month Beta 1.22
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.08

Options Overview Details

View History
  • Implied Volatility 151.58% ( +22.28%)
  • Historical Volatility 69.66%
  • IV Percentile 81%
  • IV Rank 29.21%
  • IV High 494.27% on 12/16/24
  • IV Low 10.14% on 06/14/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 3
  • Volume Avg (30-Day) 77
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 2,790
  • Open Int (30-Day) 2,744

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.32
  • Growth Rate Est. (year over year) +312,287.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.45 +15.10%
on 12/20/24
3.44 -18.02%
on 11/25/24
-0.59 (-17.30%)
since 11/22/24
3-Month
2.45 +15.10%
on 12/20/24
4.63 -39.12%
on 09/26/24
-1.68 (-37.33%)
since 09/24/24
52-Week
2.45 +15.10%
on 12/20/24
6.97 -59.54%
on 02/29/24
-2.08 (-42.45%)
since 12/22/23

Most Recent Stories

More News
enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe

Successful Completion of All Planned Implants in GLP Study

NVNO : 2.82 (-3.09%)
enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website

Interviews with participating patients from the VenoValve® U.S. Pivotal Trial

NVNO : 2.82 (-3.09%)
enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium

85% Clinical Meaningful Benefit Responder Rate

NVNO : 2.82 (-3.09%)
enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval

Definitive One Year Data from PMA Application to be Presented Wednesday at 51st Annual VEITH Symposium

NVNO : 2.82 (-3.09%)
enVVeno Medical Posts Company Highlights and Materials from 2023 VEITH Symposium

- Interviews with patients from the VenoValve® pivotal study

NVNO : 2.82 (-3.09%)
enVVeno Medical Presents Positive Preliminary Device Related Material Adverse Event (MAE) Data from the VenoValve Pivotal Trial at the 50th Annual VEITH Symposium

IRVINE, CA / ACCESSWIRE / November 16, 2023 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today...

NVNO : 2.82 (-3.09%)
enVVeno Medical Reports Third Quarter 2023 Financial Results and Provides Corporate Update

- $51.4 million cash on hand sufficient to fund current operations, including multiple value driving milestones, through the end of 2025

NVNO : 2.82 (-3.09%)
JTC Team Announces Presenting Company Line Up for the Virtual Investor “Ask the CEO” Conference Being Held October 24-25, 2023

- Live video webcast interactive Q&A with participating companies -

EVFM : 0.0091 (-2.15%)
GRI : 0.7700 (+2.15%)
MBRX : 1.8200 (+5.20%)
XBIO : 4.15 (+1.47%)
AREC : 1.0350 (-0.48%)
CNSP : 0.1090 (unch)
NVNO : 2.82 (-3.09%)
PALI : 1.7100 (-2.29%)
enVVeno Medical to Participate at the Virtual Investor Ask the CEO Conference

Live moderated webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Wednesday, October 25th at 12:00 PM ET

NVNO : 2.82 (-3.09%)
enVVeno Medical Achieves Full Enrollment for VenoValve U.S. Pivotal Trial

- 18 VenoValve patients enrolled over the final two months of the study

NVNO : 2.82 (-3.09%)

Business Summary

enVVeno Medical Corporation is a medical device company. It focuses in the treatment of venous disease. enVVeno Medical Corporation, formerly known as Hancock Jaffe Laboratories Inc., is based in IRVINE, CA.

See More

Key Turning Points

3rd Resistance Point 3.08
2nd Resistance Point 3.01
1st Resistance Point 2.92
Last Price 2.82
1st Support Level 2.76
2nd Support Level 2.69
3rd Support Level 2.60

See More

52-Week High 6.97
Fibonacci 61.8% 5.24
Fibonacci 50% 4.71
Fibonacci 38.2% 4.18
Last Price 2.82
52-Week Low 2.45

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar